

NDA 22000-S27

## **SUPPLEMENT APPROVAL**

Takeda Pharmaceuticals  
Attention: Lakshmi Prasanna Palle  
Senior Manager, Global Regulatory Strategy  
95 Hayden Avenue  
Lexington, MA 02421

Dear Lakshmi Prasanna Palle:<sup>1</sup>

Please refer to your supplemental new drug application (sNDA) dated and received September 5, 2023, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FDCA) for Lialda (mesalamine) delayed-release tablets.

We also refer to our letter dated August 9, 2023, notifying you, under Section 505(o)(4) of the FDCA, of new safety information that we have determined should be included in the labeling for mesalamine or products converted to mesalamines. This information pertains to the potential for urine discoloration upon contact with surfaces or water treated with hypochlorite-containing bleach because it may be worrisome or affect continued patient adherence to drug therapy.

This supplemental new drug application provides for revisions to the labeling for Lialda, consistent with our August 9, 2023 letter.

### **APPROVAL & LABELING**

We have completed our review of this application, as amended. It is approved, effective on the date of this letter, for use as recommended in the enclosed agreed-upon labeling.

### **CONTENT OF LABELING**

As soon as possible, but no later than 14 days from the date of this letter, submit the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format using the FDA automated drug registration and listing system (eLIST), as described at FDA.gov.<sup>2</sup> Content of labeling must be identical to the enclosed labeling (text for the Prescribing Information), with the addition of any labeling changes in pending “Changes

---

<sup>1</sup> We update guidances periodically. For the most recent version of a guidance, check the FDA Guidance Documents Database <https://www.fda.gov/RegulatoryInformation/Guidances/default.htm>.

<sup>2</sup> <http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm>

Being Effected” (CBE) supplements, as well as annual reportable changes not included in the enclosed labeling.

Information on submitting SPL files using eList may be found in the guidance for industry *SPL Standard for Content of Labeling Technical Qs and As*.<sup>3</sup>

The SPL will be accessible from publicly available labeling repositories.

Also within 14 days, amend all pending supplemental applications that include labeling changes for this NDA, including CBE supplements for which FDA has not yet issued an action letter, with the content of labeling [21 CFR 314.50(I)(1)(i)] in Microsoft Word format, that includes the changes approved in this supplemental application, as well as annual reportable changes. To facilitate review of your submission(s), provide a highlighted or marked-up copy that shows all changes, as well as a clean Microsoft Word version. The marked-up copy should provide appropriate annotations, including supplement number(s) and annual report date(s).

## **REPORTING REQUIREMENTS**

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, call Jacqueline LeeHoffman, Safety Regulatory Project Manager, at (240) 402-8689.

Sincerely,

*{See appended electronic signature page}*

Joyce Korvick, M.D., M.P.H.  
Deputy Director for Safety  
Division of Gastroenterology (DG)  
Office of Immunology and Inflammation (OII)  
Center for Drug Evaluation and Research

### ENCLOSURE(S):

- Content of Labeling
  - Prescribing Information

---

<sup>3</sup> We update guidances periodically. For the most recent version of a guidance, check the FDA Guidance Documents Database <https://www.fda.gov/RegulatoryInformation/Guidances/default.htm>.

-----  
**This is a representation of an electronic record that was signed electronically. Following this are manifestations of any and all electronic signatures for this electronic record.**  
-----

/s/  
-----

JOYCE A KORVICK  
10/24/2023 10:31:42 AM